Societies embrace gene therapy but resist genetic change in crops

A growing body of research highlights a pronounced societal inconsistency: therapeutic gene modification (gene therapy) in human medicine is broadly accepted...

What Happened

A growing body of research highlights a pronounced societal inconsistency: therapeutic gene modification (gene therapy) in human medicine is broadly accepted by the public, while genetic modification of food crops continues to face strong resistance across many societies, including India.
This asymmetry persists despite both technologies using similar molecular tools — including CRISPR-Cas9 — to alter genetic sequences with precision.
In India, genome-edited crops (which do not contain foreign genes) have received regulatory facilitation since a 2022 exemption by the Ministry of Environment, Forest, and Climate Change (MoEFCC), yet public resistance and court scrutiny remain.
The Supreme Court of India in March 2025 directed the central government to formulate a comprehensive national policy on GM crop regulation and adoption.
Two genome-edited rice varieties (Samba Mahsuri and MTU-1010) were cleared for release in India, and a genome-edited mustard variety is in advanced field trials.
Research indicates that public trust in institutions, perceived corporate intent, food sovereignty concerns, and communication failures — not the science itself — drive crop GM resistance.

Static Topic Bridges

Gene Therapy — Mechanism and Types

Gene therapy is the clinical use of nucleic acid sequences to treat or prevent disease by correcting, replacing, or supplementing defective genes in a patient's cells. It involves delivering a therapeutic gene into target cells using viral vectors (such as adeno-associated viruses) or newer non-viral methods (such as lipid nanoparticles). There are two main types: somatic gene therapy and germline gene therapy.

Somatic gene therapy: Targets non-reproductive cells; effects are not heritable; approved for clinical use globally for conditions like SMA (Spinal Muscular Atrophy), haemophilia, and inherited blindness; India's ICMR guidelines permit this
Germline gene therapy: Modifies eggs, sperm, or early embryos; effects are heritable and affect all future generations; universally prohibited for clinical use; the He Jiankui case (2018, China) was an illegal germline edit in human embryos
CRISPR-Cas9: The most widely used gene-editing tool; enables precise, targeted modifications to DNA sequences; used in both human therapy and crop development
India's regulatory position: ICMR guidelines prohibit germline gene editing; somatic cell editing for therapy is permitted under clinical trial regulations

Connection to this news: The public broadly accepts somatic gene therapy because it treats individual patients without heritable effects, and the risk-benefit calculation is clearly personal. The resistance to crop modification reflects different concerns — corporate control of seeds, biodiversity loss, and perceived ecosystem risks — illustrating how identical tools generate vastly different ethical and social responses.

Genetically Modified (GM) Crops vs. Genome-Edited (GE) Crops — Key Distinctions

Traditional transgenic GM crops involve inserting foreign DNA from another organism into the target crop's genome (e.g., Bt toxin gene from Bacillus thuringiensis inserted into cotton or brinjal). In contrast, genome-edited (GE) crops use tools like CRISPR-Cas9 to make precise edits within the crop's own genome — without adding any foreign genetic material — to enhance traits such as disease resistance, drought tolerance, or nutritional value.

GM (transgenic): Contains exogenous (foreign) DNA; subject to full biosafety regulation globally
GE (genome-edited): No foreign DNA; mimics natural mutation; increasingly treated as non-transgenic by regulators
India's 2022 MoEFCC policy: GE crops free of foreign DNA are exempt from the full GM biosafety regime; require only IBSC certification instead of full GEAC approval
Examples of GE crops under development in India: Drought-resistant rice, low-pungency mustard, disease-resistant banana
Approved GE varieties (India): Two rice varieties — Samba Mahsuri (blast-resistant) and MTU-1010

Connection to this news: The regulatory and social distinction between GM and GE crops is central to the article's argument. While GE crops technically avoid the "foreign DNA" concern that drives GM resistance, public confusion between the two categories perpetuates opposition to genome-edited crops as well.

GEAC and India's GM/GE Regulatory Framework

The Genetic Engineering Appraisal Committee (GEAC) is the apex body under the Ministry of Environment, Forest, and Climate Change for evaluating the environmental safety of genetically engineered organisms in India. It operates under the Environment Protection Act, 1986. Its decisions are backed by the Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Micro-organisms/Genetically Engineered Organisms or Cells (1989 Rules under EPA).

GEAC establishment: Under EPA 1986; constituted under the 1989 Rules
Only approved GM food crop in India: Bt cotton (commercially, since 2002); Bt brinjal approved by GEAC in 2009 but placed under moratorium
GM mustard (DMH-11 / Dhara Mustard Hybrid): GEAC approved for environmental release in October 2022; developed by Delhi University; first edible transgenic crop approved by GEAC
IBSC: Institutional Biosafety Committee — certifies GE crops without foreign DNA under the 2022 MoEFCC exemption
Supreme Court direction (March 2025): Government to formulate national GM crop policy
India has banned Bt brinjal cultivation since 2010 moratorium

Connection to this news: India's regulatory evolution — distinguishing between transgenic GM and genome-edited GE crops since 2022 — is a policy response to precisely the social-acceptance asymmetry described in the article. Making the regulatory process science-based and transparent is essential to bridging the gap between societal acceptance of gene therapy and continued resistance to crop biotechnology.

Bioethics and the Double Standard Debate

Bioethics examines the moral implications of biological research and healthcare. The public acceptance asymmetry between gene therapy and GM crops raises bioethical questions about perceived intent (healing a sick person vs. serving corporate interests), agency (consent by adult patients vs. no consent from nature), and externalities (contained clinical effects vs. open environmental release). Research consistently shows that trust in institutions — government, corporations, scientists — is the single most powerful predictor of public acceptance of biotechnology.

Nuffield Council on Bioethics (UK): Published landmark 1999 report on GM crops' ethical dimensions; updated guidance for gene editing ongoing
Perceived distinctions driving asymmetry: Medical benefit is direct and personal; crop modification is perceived as benefiting corporations more than consumers or farmers
Communication failures cited: Developers using euphemistic renaming ("gene editing" vs. "GMO") erodes public trust by appearing dishonest
India: No formal consumer perception study on GE crops conducted (as of 2024); resistance is diffuse and driven by civil society organisations

Connection to this news: The societal double standard discussed in the article is not irrational — it reflects deeper questions about who controls food systems, what risks are acceptable, and whether regulatory institutions can be trusted. Addressing this asymmetry requires both scientific literacy campaigns and meaningful public participation in governance of biotechnology.

Key Facts & Data

India's only commercially cultivated GM crop: Bt cotton (since 2002)
Bt brinjal: GEAC approved 2009; moratorium imposed 2010 (still in force)
GM mustard (DMH-11): GEAC environmental release approval in October 2022; India's first approved edible transgenic crop
MoEFCC 2022 exemption: GE crops with no foreign DNA exempt from full GM biosafety regime
Supreme Court direction: March 2025 — frame national GM crop policy
Approved GE rice varieties in India: Samba Mahsuri, MTU-1010
GEAC: Under MoEFCC; established under EPA 1986 / 1989 Rules
ICMR position: Somatic gene therapy permitted; germline editing prohibited
He Jiankui case: 2018, China — illegal human germline CRISPR edit (CCR5 gene in twins)
CRISPR-Cas9: Developed by Jennifer Doudna and Emmanuelle Charpentier — Nobel Prize in Chemistry 2020
Brazil public acceptance (research data): Gene modification for drugs/vaccines 87% > crops 81% > food 66%
India's gene editing regulatory bodies: GEAC (transgenic), IBSC (GE without foreign DNA)